Therefore, deleting BLIMP1 would block the differentiation of B cells into plasma cells. TNFAIP3 participates in terminating NF-κB signaling, and its loss of function by deletion might enhance inflammatory, autoimmune, and malignant human diseases, including WM [30, 31]. Here, NFKB1 is linked to cancer.